Shuttle PharmaceuticalsSHPH
SHPH
About: Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
Employees: 9
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
33% more funds holding
Funds holding: 6 [Q4 2024] → 8 (+2) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
6.13% less ownership
Funds ownership: 9.72% [Q4 2024] → 3.59% (-6.13%) [Q1 2025]
71% less capital invested
Capital invested by funds: $306K [Q4 2024] → $87.5K (-$219K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for SHPH.
Financial journalist opinion
Based on 3 articles about SHPH published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) announces that the reverse stock split will become effective on June 16, 2025, at 12:01 a.m.
Neutral
GlobeNewsWire
3 days ago
Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announces that its Board of Directors have approved a proposed reverse stock split of its common stock at a ratio of 25-for-1. The proposed action remains subject to approval by Nasdaq and, if approved, the Company will issue a subsequent announcement disclosing the effective date.
Neutral
GlobeNewsWire
1 week ago
Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors
GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025.
Neutral
GlobeNewsWire
1 month ago
Shuttle Pharma Provides Corporate Update
GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update.
Neutral
GlobeNewsWire
1 month ago
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has nearly achieved 50% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma, with treatment sites reporting that the drug has been well tolerated and toxicity no greater than 2 on a scale of 1-5. Further, 84% of the enrolled patients have completed all seven cycles. Shuttle has begun analyzing pharmacokinetic/pharmacodynamic samples to compare the relationship between dose and response in terms of the extent and duration of Ropidoxuridine's action. Our objective is to finalize enrollment later this year with follow up and data read out in 2026.
Neutral
GlobeNewsWire
1 month ago
Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
GAITHERSBURG, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 2:30 p.m.
Neutral
GlobeNewsWire
2 months ago
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic and Therapeutic programs
Neutral
GlobeNewsWire
3 months ago
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the closing of its previously announced underwritten public offering of 19,166,667 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.30 per share (the “Offering”). The aggregate gross proceeds to Shuttle Pharma from the Offering was approximately $5.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by Shuttle Pharma.
Neutral
GlobeNewsWire
3 months ago
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the pricing of an underwritten public offering of 19,166,667 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.30 per share (the “Offering”). The aggregate gross proceeds to Shuttle Pharma from the Offering are expected to be approximately $5.75 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Shuttle Pharma. The Offering is expected to close on March 13, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
3 months ago
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activities Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activities
Charts implemented using Lightweight Charts™